LEGAL PROCEEDINGS
−Removed: March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
−Removed: The complaint is captioned Blum v.
+Added: The Company is subject to claims and legal proceedings
+Added: that arise during the course of business.
+Added: The Company is currently subject to the following lawsuits:
+Added: 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York (the “Initial
+Added: The complaint was captioned Blum v.
Anavex Life Sciences, Corp.
−Removed: et al., case number 1:24-cv-01910, and names the Company and Christopher
−Removed: Missling as Defendants.
−Removed: The complaint alleges violations of the Securities and Exchange Act of 1934 resulting from disclosures and statements
−Removed: made about certain clinical trials for ANAVEX ® 2-73.
−Removed: On July 12, 2024, the lead plaintiff filed an amended complaint.
−Removed: Company believes the complaint is without merit.
−Removed: The Company is vigorously pursuing its defenses and a potential dismissal of all claims
−Removed: asserted in the lawsuit.
−Removed: On May 8, 2024,
−Removed: another purported shareholder of the Company filed a similar lawsuit against the same defendants that raised similar allegations and in
−Removed: addition, raised allegations related to disclosures and statements made about the AVATAR trial.
−Removed: The shareholder sought to consolidate
−Removed: the cases and be appointed lead plaintiff of the consolidated action.
−Removed: The court denied the consolidation motion and lead plaintiff motion
−Removed: on June 13, 2024.
−Removed: The Company plans to vigorously defend the lawsuit.
+Added: et al., case number 1:24-cv-01910, and it named the Company
+Added: and Christopher Missling as Defendants.
+Added: The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures
+Added: and statements made with respect to certain clinical trials for ANAVEX ® 2-73 related to Rett syndrome (the “March
+Added: 2024 Complaint”).
+Added: At a hearing on or about June 13, 2024, the Court named another purported Company shareholder, Quintessa Huey,
+Added: as lead plaintiff with respect to the March 2024 Complaint.
+Added: An Amended Complaint was filed by the appointed lead plaintiff on July 12,
+Added: 2024, which asserts allegations related to purported violations of Section 10(b) of the Securities Exchange Act tied to disclosures associated
+Added: with the same clinical trials related to Rett Syndrome, and which names the Company and Christopher Missling as defendants.
+Added: Complaint seeks unspecified damages, as well as costs, including counsel and expert witness fees, on behalf of class of investors who
+Added: purchased stock of the Company on the NASDAQ during the period February 1, 2022 through January 1, 2024.
+Added: The defendants filed a motion
+Added: to dismiss the complaint.
+Added: The motion to dismiss is fully-briefed and awaiting a decision by the Court.
On May 8, 2024,
−Removed: a purported shareholder filed a derivative lawsuit on behalf of the Company against the board of directors.
−Removed: The complaint asserts various
−Removed: common law claims (including breach of fiduciary duty) and violation of Section 14(a) regarding the same allegations at issue in the two
−Removed: purported class action lawsuits related to disclosures and statements made about certain clinical trials.
−Removed: The Company is named as a Nominal
−Removed: The defendants plan to vigorously defend the lawsuit.
+Added: a similar complaint was filed in the same court by Kenneth Downing (case no.
+Added: 1:2024-cv-03529), a purported shareholder of the Company,
+Added: against the same defendants as the March 2024 Complaint.
+Added: The defendants filed a motion to dismiss the complaint.
+Added: Plaintiff Downing voluntarily
+Added: dismissed his complaint subsequent to the filing of the motion to dismiss.
+Added: May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), Christopher Missling, and members of the Company’s
+Added: Board of Directors in the U.S.
+Added: District Court for the District of Nevada by another purported shareholder named Denise Deangelis.
+Added: complaint asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a) of the Securities Exchange
+Added: Act regarding the same or similar allegations at issue in the two purported class action lawsuits related to disclosures and statements
+Added: made about certain clinical trials related to Rett Syndrome.
+Added: On January 22, 2025, pursuant to a stipulation of the parties, the Court
+Added: entered an order staying this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided
+Added: District Court for the Southern District of New York.
know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
5 unchanged sentences
discussed in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024,
−Removed: filed with the SEC on November 27, 2023.
+Added: filed with the SEC on December 23, 2024.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.